operties of CHD patients’ serum manifested in cell culture. Atherosclerosis, 81, 183-189. doi:10.1016/0021-9150(90)90065-Q

[26]   Kacharava, A.G., Tertov, V.V. and Orekhov, A.N. (1993) Autoantibodies against low-density lipoprotein and atherogenic potential of blood. Annals of Medicine, 25, 551-555.

[27]   Tertov, V.V., Orekhov, A.N., Kacharava, A.G., Sobenin, I.A., Perova, N.V. and Smirnov, V.N. (1990) Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis. Experimental and Molecular Pathology, 52, 300-308. doi:10.1016/0014-4800(90)90071-K

[28]   Orekhov, A.N., Kalenich, O.S., Tertov, V.V. and Novikov, I.D. (1991) Lipoprotein immune complexes as markers of atherosclerosis. International Journal of Tissue Reactions, 13, 233-236.

[29]   Orekhov, A.N., Kalenich, O.S., Tertov, V.V., Perova, N.V., Novikov, I.D., Lyakishev, A.A., Deev, A.D. and Ruda, M.Y. (1995) Diagnostic value of immune cholesterol as a marker for atherosclerosis. Journal of Cardiovascular Risk, 2, 459-466. doi:10.1097/00043798-199510000-00011

[30]   Sobenin, I.A., Karagodin, V.P., Melnichenko, A.A., Bobryshev, Y.V. and Orekhov, A.N. (2013) Diagnostic and prognostic value of low density lipoprotein-containing circulating immune complexes in atherosclerosis. Journal of Clinical Immunology, 33, 489-495. doi:10.1007/s10875-012-9819-4

[31]   Sobenin, I.A., Orekhova, V.A., Melnichenko, A., Bobryshev, Y.V. and Orekhov, A.N. (2012) Low density lipoprotein-containing circulating immune complexes have better prognostic value in carotid intima-media thickness progression than other lipid parameters. International Journal of Cardiology, 163, 747-748. doi:10.1016/j.ijcard.2012.09.175

[32]   Orekhov, A.N., Tertov, V.V., Mukhin, D.N., Koteliansky, V.E., Glukhova, M.A., Frid, M.G., Sukhova, G.K., Khashimov, K.A. and Smirnov, V.N. (1989) Insolubilization of low density lipoprotein induces cholesterol accumulation in cultured subendothelial cells of human aorta. Atherosclerosis, 79, 59-70. doi:10.1016/0021-9150(89)90034-8

[33]   Glukhova, M.A., Kabakov, A.E., Frid, M.G., Ornatsky, O.I., Belkin, A.M., Mukhin, D.N., Orekhov, A.N., Koteliansky, V.E. and Smirnov, V.N. (1988) Modulation of human aorta smooth muscle cell phenotype: A study of muscle-specific variants of vinculin, caldesmon, and actin expression. Proceedings of the National Academy of Sciences of the United States of America, 85, 9542-9546. doi:10.1073/pnas.85.24.9542

[34]   Orekhov, A.N., Tertov, V.V., Mukhin, D.N., Koteliansky, V.E., Glukhova, M.A., Khashimov, K.A. and Smirnov, V.N. (1987) Association of low-density lipoprotein with particulate connective tissue matrix components enhances cholesterol accumulation in cultured subendothelial cells of human aorta. Biochimica et Biophysica Acta, 928, 251-258. doi:10.1016/0167-4889(87)90183-2

[35]   Melnichenko, A.A., Aksenov, D.V., Myasoedova, V.A., Panasenko, O.M., Yaroslavov, A.A., Sobenin, I.A., Bobryshev, Y.V. and Orekhov, A.N. (2012) Pluronic block copolymers inhibit low density lipoprotein self-association. Lipids, 47, 995-1000. doi:10.1007/s11745-012-3699-5

[36]   Tertov, V.V., Orekhov, A.N., Sobenin, I.A., Gabbasov, Z.A., Popov, E.G., Yaroslavov, A.A. and Smirnov, V.N. (1992) Three types of naturally occurring modified lipoproteins induce intracellular lipid accumulation due to lipoprotein aggregation. Circulation Research, 71, 218-228. doi:10.1161/01.RES.71.1.218

[37]   Rekhter, M.D., Andreeva, E.R., Mironov, A.A. and Orekhov, A.N. (1991) Three-dimensional cytoarchitecture of normal and atherosclerotic intima of human aorta. American Journal of Pathology, 138, 569-580.

[38]   Orekhov, A.N., Andreeva, E.R., Krushinsky, A.V. and Smirnov, V.N. (1984) Primary cultures of enzyme-isolated cells from normal and atherosclerotic human aorta. Medical Biology, 62, 255-259.

[39]   Orekhov, A.N., Tertov, V.V., Novikov, I.D., Krushinsky, A.V., Andreeva, E.R., Lankin V.Z. and Smirnov, V.N. (1985) Lipids in cells of atherosclerotic and uninvolved human aorta: I. lipid composition of aortic tissue and enzyme isolated and cultured cells. Experimental and Molecular Pathology, 42, 117-137. doi:10.1016/0014-4800(85)90022-X

[40]   Orekhov, A.N., Krushinsky, A.V., Andreeva, E.R., Repin V.S. and Smirnov, V.N. (1986) Adult human aortic cells in primary culture: Heterogeneity in shape. Heart and Vessels, 2, 193-201. doi:10.1007/BF02059968

[41]   Yamada, S., Guo, X., Yoshizawa, M., Li, Z., Matsuyama, A., Hashimoto, H. and Sasaguri, Y. (2011) Primary desmoplastic cutaneous leiomyosarcoma associated with high MIB-1 labeling index: A teaching case giving rise to diagnostic difficulties on a small biopsy specimen. Pathology, Research and Practice, 207, 728-732. doi:10.1016/j.prp.2011.08.008

[42]   Orekhov, A.N., Kosykh, V.A., Repin, V.S. and Smirnov, V.N. (1983) Cell proliferation in normal and atherosclerotic human aorta. II. Autoradiographic observation on deoxyribonucleic acid synthesis in primary cell culture. Laboratory Investigation, 48, 749-754.

[43]   Orekhov, A.N., Tertov, V.V., Kudryashov, S.A., Khashimov, Kh.A. and Smirnov, V.N. (1986) Primary culture of human aortic intima cells as a model for testing anti-atherosclerotic drugs. Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipid-lowering agents. Atherosclerosis, 60, 101-110. doi:10.1016/0021-9150(86)90002-X

[44]   Chazov, E.I., Tertov, V.V., Orekhov, A.N., Lyakishev, A.A., Perova, N.V., Kurdanov, Kh.A., Khashimov, Kh.A., Novikov, I.D. and Smirnov, V.N. (1986) Atherogenicity of blood serum from patients with coronary heart disease. Lancet, 2, 595-598. doi:10.1016/S0140-6736(86)92426-8

[45]   Tertov, V.V., Orekhov, A.N., Ryong, Li.Hwa. and Smirnov, V.N. (1988) Intracellular cholesterol accumulation is accompanied by enhanced proliferative activity of human aortic intimal cells. Tissue & Cell, 20, 849-854. doi:10.1016/0040-8166(88)90026-2

[46]   Tertov, V.V., Orekhov, A.N., Martsenyuk, O.N., Perova, N.V. and Smirnov, V.N. (1989) Low density lipoproteins isolated from the blood of patients with coronary heart disease induce the accumulation of lipids in human aortic cells. Experimental and Molecular Pathology, 50, 337-347. doi:10.1016/0014-4800(89)90043-9

[47]   Orekhov, A.N. (1990) In vitro models of antiatherosclerotic effects of cardiovascular drugs. The American Journal of Cardiology, 66, 23I-28I. doi:10.1016/0002-9149(90)91260-D

[48]   Palatini, P. (2009) Elevated heart rate in cardiovascular diseases: A target for treatment? Progress in Cardiovascular Diseases, 52, 46-60. doi:10.1016/j.pcad.2009.05.005

[49]   Schulman, I.H., Zachariah, M. and Raij, L. (2005) Calcium channel blockers, endothelial dysfunction, and combination therapy. Aging Clinical and Experimental Research, 17, 40-45.

[50]   Orekhov, A.N., Baldenkov, G.N., Tertov, V.V., Ryong, Li.Hwa., Kozlov, S.G., Lyakishev, A.A., Tkachuk, V.A., Ruda, M.Ya. and Smirnov, V.N. (1988) Cardiovascular drugs and atherosclerosis: Effects of calcium antagonists, beta-blockers, and nitrates on atherosclerotic characteristics of human aortic cells. Journal of Cardiovascular Pharmacology, 12, S66-S68. doi:10.1097/00005344-198812006-00017

[51]   Loaldi, A., Polese, A., Montorsi, P., Cesare, N.De., Fabbiocchi, F., Ravagnani, P. and Guazzi, M.D. (1989) Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris. The American Journal of Cardiology, 64, 433-439. doi:10.1016/0002-9149(89)90417-7

[52]   Orekhov, A.N., Baldenkov, G.N., Tertov, V.V., Ruda, M.Ya., Khashimov, Kh.A., Kudryashov, S.A., Li, H.R., Kozlov, S.G., Lyakishev, A.A., Tkachuk V.A. and Smirnov, V.N. (1990) Antiatherosclerotic effects of calcium antagonists. Study in human aortic cell culture. Herz, 15, 139-145.

[53]   Orekhov, A.N. and Tertov, V.V. (1997) In vitro effect of garlic powder extract on lipid content in normal and atherosclerotic human aortic cells. Lipids, 32, 1055-1060. doi:10.1007/s11745-997-0136-7

[54]   Orekhov, A.N. and Grünwald, J. (1997) Effects of garlic on atherosclerosis. Nutrition, 13, 656-663. doi:10.1016/S0899-9007(97)83010-9

[55]   Orekhov, A.N., Sobenin, I.A., Korneev, N.V., Kirichenko, T.V., Myasoedova, V.A., Melnichenko, A.A., Balcells, M., Edelman, E.R. and Bobryshev, Y.V. (2012) Anti-atherosclerotic therapy based on botanicals. Recent Patents on Cardiovascular Drug Discovery.

[56]   Koscielny, J., Klüssendorf, D., Latza, R., Schmitt, R., Radtke, H., Siegel, G. and Kiesewetter, H. (1999) The antiatherosclerotic effect of Allium sativum. Atherosclerosis, 144, 237-249. doi:10.1016/S0021-9150(99)00060-X

[57]   Crouse 3rd, J.R., Byington, R.P., Bond, M.G., Espeland, M.A., Craven, T.E., Sprinkle, J.W., McGovern, M.E. and Furberg, C.D. (1995) Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). American Journal of Cardiology, 75, 455-459. doi:10.1016/S0002-9149(99)80580-3

[58]   Salonen, R., Nyyssonen, K., Porkkala, E., Rummukainen, J., Belder, R., Park, J.S. and Salonen, J.T. (1995) Kuopio atherosclerosis prevention study (KAPS). A populationbased primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation, 92, 1758-1764. doi:10.1161/01.CIR.92.7.1758

[59]   Smilde, T.J., van Wissen, S., Wollersheim, H., Trip, M.D., Kastelein, J. and Stalenhoef, A.F. (2001) Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet, 357, 577-581. doi:10.1016/S0140-6736(00)04053-8

[60]   Pitt, B., Byington, R.P., Furberg, C.D., Hunninghake, D.B., Mancini, G.B., Miller, M.E. and Riley, W. (2000) Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Prevent investigators. Circulation, 102, 1503-1510. doi:10.1161/01.CIR.102.13.1503

[61]   Blankenhorn, D.H., Selzer, R.H., Crawford, D.W., Barth, J.D., Liu, C.R., Liu, C.H., Mack W.J. and Alaupovic, P. (1993) Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two-and four-year reduction of intima-media thickness Measured by ultrasound. Circulation, 88, 20-28. doi:10.1161/01.CIR.88.1.20

[62]   Hodis, H.N. (1995) Reversibility of atherosclerosis-evolving perspectives from two arterial imaging clinical trials: The cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study. Journal of Cardiovascular Pharmacology, 25, S25-S31.

[63]   Blankenhorn, D.H., Azen, S.P., Kramsch, D.M., Mack, W.J., Cashin-Hemphill, L., Hodis, H.N., DeBoer, L.W., Mahrer, P.R., Masteller, M.J., Vailas, L.I., Alaupovic, P., Hirsch L.J., MARS Research Group (1993) Coronary angiographic changes with lovastatin therapy. The monitored atherosclerosis regression study (MARS). Annals of Internal Medicine, 119, 969-976. doi:10.7326/0003-4819-119-10-199311150-00002

[64]   Zanchetti, A., Rosei, E.A., Dal Palù, C., Leonetti, G., Magnani, B. and Pessina, A. (1998) The verapamil in hypertension and atherosclerosis study (VHAS): Results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension, 16, 1667-1676. doi:10.1097/00004872-199816110-00014

[65]   Libby, P. (2006) Inflammation and cardiovascular disease mechanisms. The American Journal of Clinical Nutrition, 83, 456S-460S.

[66]   Aidinian, G., Weiswasser, J.M. and Arora, S. (2006) Carotid plaque morphologic characteristics. Perspectives in Vascular Surgery and Endovascular Therapy, 18, 63-70. doi:10.1177/153100350601800124

[67]   Daugherty, A., Webb, N.R., Rateri, D.L. and King, V.L. (2005) The immune system and atherogenesis. Cytokine regulation of macrophage functions in atherogenesis. Journal of Lipid Research, 46, 1812-1822. doi:10.1194/jlr.R500009-JLR200

[68]   Burger, H.G., Maclennan, A.H., Huang, K.E. and Castelo-Branco, C. (2012) Evidence-based assessment of the impact of the WHI on women’s health. Climacteric, 15, 281-287. doi:10.3109/13697137.2012.655564

[69]   de Villiers, T.J. and Stevenson, J.C. (2012) The WHI: The effect of hormone replacement therapy on fracture prevention. Climacteric, 15, 263-266. doi:10.3109/13697137.2012.659975

[70]   Ellis, M.J., Suman, V.J., Hoog, J., Lin, L., Snider, J., Prat, A., Parker, J.S., Luo, J., DeSchryver, K., Allred, D.C., Esserman, L.J., Unzeitig, G.W., Margenthaler, J., Babiera, G.V., Marcom, P.K., Guenther, J.M., Watson, M.A., Leitch, M., Hunt, K. and Olson, J.A. (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline pam50-based intrinsic subtype-ACOSOG Z1031. Journal of Clinical Oncology, 29, 2342-2349. doi:10.1200/JCO.2010.31.6950

[71]   Smith, N.L., Wiley, J.R., Legault, C., Rice, K.M., Heckbert, S.R., Psaty, B.M., Tracy, R.P. and Cushman, M. (2008) Effect of progestogen and progestogen type on hemostasis measures in postmenopausal women: The postmenopausal estrogen/progestin intervention (pepi) study. Menopause, 15, 1145-1150. doi:10.1097/gme.0b013e3181775eca

[72]   Masood, D.E., Roach, E.C., Beauregard, K.G. and Khalil, R.A. (2010) Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease. Current Drug Metabolism, 11, 693-714. doi:10.2174/138920010794233477

[73]   Pellegrini, C.N., Vittinghoff, E., Lin, F., Hulley, S.B. and Marcus, G.M. (2009) Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: The HERS trial. Heart, 95, 704-708. doi:10.1136/hrt.2008.154054

[74]   Slevin, M., Ahmed, N., Wang, Q., McDowell, G. and Badimon, L. (2012) Unique vascular protective properties of natural products: Supplements or future main-line drugs with significant anti-atherosclerotic potential?. Vascular Cell, 4, 9. doi:10.1186/2045-824X-4-9

 
 
Top